The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting
Culprits of cancer development, metastasis, and drug resistance, cancer stem cells (CSCs) are characterized by specific markers, active developmental signaling pathways, metabolic plasticity, increased motility, invasiveness, and epithelial-mesenchymal transition. In breast cancer, these cells are o...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.791696/full |
| _version_ | 1819285103026634752 |
|---|---|
| author | Olivia L. Walker Margaret L. Dahn Melanie R. Power Coombs Melanie R. Power Coombs Paola Marcato Paola Marcato |
| author_facet | Olivia L. Walker Margaret L. Dahn Melanie R. Power Coombs Melanie R. Power Coombs Paola Marcato Paola Marcato |
| author_sort | Olivia L. Walker |
| collection | DOAJ |
| description | Culprits of cancer development, metastasis, and drug resistance, cancer stem cells (CSCs) are characterized by specific markers, active developmental signaling pathways, metabolic plasticity, increased motility, invasiveness, and epithelial-mesenchymal transition. In breast cancer, these cells are often more prominent in aggressive disease, are amplified in drug-resistant tumors, and contribute to recurrence. For breast cancer, two distinct CSC populations exist and are typically defined by CD44+/CD24- cell surface marker expression or increased aldehyde dehydrogenase (ALDH) activity. These CSC populations share many of the same properties but also exhibit signaling pathways that are more active in CD44+/CD24- or ALDH+ populations. Understanding these CSC populations and their shared or specific signaling pathways may lead to the development of novel therapeutic strategies that will improve breast cancer patient outcomes. Herein, we review the current evidence and assess published patient tumor datasets of sorted breast CSC populations for evidence of heightened prostaglandin E2 (PGE2) signaling and activity in these breast CSC populations. PGE2 is a biologically active lipid mediator and in cancer PGE2 promotes tumor progression and poor patient prognosis. Overall, the data suggests that PGE2 signaling is important in propagating breast CSCs by enhancing inherent tumor-initiating capacities. Development of anti-PGE2 signaling therapeutics may be beneficial in inhibiting tumor growth and limiting breast CSC populations. |
| first_indexed | 2024-12-24T01:57:56Z |
| format | Article |
| id | doaj.art-ea672c930451471e8cc2a6086fc722a4 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-24T01:57:56Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-ea672c930451471e8cc2a6086fc722a42022-12-21T17:21:31ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-01-011110.3389/fonc.2021.791696791696The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential TargetingOlivia L. Walker0Margaret L. Dahn1Melanie R. Power Coombs2Melanie R. Power Coombs3Paola Marcato4Paola Marcato5Pathology, Dalhousie University, Halifax, NS, CanadaPathology, Dalhousie University, Halifax, NS, CanadaPathology, Dalhousie University, Halifax, NS, CanadaBiology, Acadia University, Wolfville, NS, CanadaPathology, Dalhousie University, Halifax, NS, CanadaMicrobiology and Immunology, Dalhousie University, Halifax, NS, CanadaCulprits of cancer development, metastasis, and drug resistance, cancer stem cells (CSCs) are characterized by specific markers, active developmental signaling pathways, metabolic plasticity, increased motility, invasiveness, and epithelial-mesenchymal transition. In breast cancer, these cells are often more prominent in aggressive disease, are amplified in drug-resistant tumors, and contribute to recurrence. For breast cancer, two distinct CSC populations exist and are typically defined by CD44+/CD24- cell surface marker expression or increased aldehyde dehydrogenase (ALDH) activity. These CSC populations share many of the same properties but also exhibit signaling pathways that are more active in CD44+/CD24- or ALDH+ populations. Understanding these CSC populations and their shared or specific signaling pathways may lead to the development of novel therapeutic strategies that will improve breast cancer patient outcomes. Herein, we review the current evidence and assess published patient tumor datasets of sorted breast CSC populations for evidence of heightened prostaglandin E2 (PGE2) signaling and activity in these breast CSC populations. PGE2 is a biologically active lipid mediator and in cancer PGE2 promotes tumor progression and poor patient prognosis. Overall, the data suggests that PGE2 signaling is important in propagating breast CSCs by enhancing inherent tumor-initiating capacities. Development of anti-PGE2 signaling therapeutics may be beneficial in inhibiting tumor growth and limiting breast CSC populations.https://www.frontiersin.org/articles/10.3389/fonc.2021.791696/fullprostaglandin E2breast cancercancer stem cellsaldehyde dehydrogenaseCD44+/CD24-EP receptors |
| spellingShingle | Olivia L. Walker Margaret L. Dahn Melanie R. Power Coombs Melanie R. Power Coombs Paola Marcato Paola Marcato The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting Frontiers in Oncology prostaglandin E2 breast cancer cancer stem cells aldehyde dehydrogenase CD44+/CD24- EP receptors |
| title | The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting |
| title_full | The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting |
| title_fullStr | The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting |
| title_full_unstemmed | The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting |
| title_short | The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting |
| title_sort | prostaglandin e2 pathway and breast cancer stem cells evidence of increased signaling and potential targeting |
| topic | prostaglandin E2 breast cancer cancer stem cells aldehyde dehydrogenase CD44+/CD24- EP receptors |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.791696/full |
| work_keys_str_mv | AT olivialwalker theprostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT margaretldahn theprostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT melanierpowercoombs theprostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT melanierpowercoombs theprostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT paolamarcato theprostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT paolamarcato theprostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT olivialwalker prostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT margaretldahn prostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT melanierpowercoombs prostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT melanierpowercoombs prostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT paolamarcato prostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting AT paolamarcato prostaglandine2pathwayandbreastcancerstemcellsevidenceofincreasedsignalingandpotentialtargeting |